Non-antiplatelet effect of clopidogrel: improving endothelial function in Chinese healthy subjects with different CYP2C19 genotype

作者：Zhang, Yin-Zhuang; Chen, Bi-Lian^*; Zhang, Wei; Cao, Xin

来源：CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2015, 42(1): 22-26.

DOI：10.1111/1440-1681.12325

• clopidogrel
• CYP2C19 genotype
• endothelial function
• flow-mediated dilation

Clopidogrel has been shown to improve endothelial function invitro and in patients with coronary artery disease. However, it remains unclear whether such an effect of clopidogrel is associated with CYP2C19 polymorphisms that determine the antiplatelet effect of clopidogrel. After genotyping, 12 healthy participants were enrolled in the study. Among them, six participants were CYP2C19*11 (extensive metabolizers; EM) and the other six participants were CYP2C19*22 or *3 (poor metabolizers; PM). All participants received 300mg clopidogel orally. Endothelial function was assessed by measurement of flow-mediated dilation of the brachial artery, and adenosine diphosphate-induced platelet aggregation was determined by using optical aggregometry at 0, 4 and 24h after administration of 300mg clopidogrel. Flow-mediated dilation was significantly higher at 4 and 24h after a loading-dose administration of clopidogrel in both the CYP2C19 EM and PM groups, but showed no significant difference between the two groups. Adenosine diphosphate-induced platelet aggregation was significantly inhibited at 4 and 24h after administration of clopidogrel in the CYP2C19 EM group. However, there was no statistical correlation between the change in flow-mediated dilation and adenosine diphosphate-induced platelet aggregation in the two CYP2C19 groups. This is the first study to report that clopidogrel improves endothelial function in healthy Chinese subjects, which is unrelated with the CYP2C19 genotype and independent of antiplatelet action.

• 出版日期2015-1
• 单位中南大学